USANA HEALTH SCIENCES, INC.— Sankey Diagram
Quarterly mode · period ending 2026-01-03 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2024 (Q4)
Revenue
$226M
↑+5.9% +$13Mvs FY2024 (Q4)
Gross Profit
$177M
↑+1.0% +$2Mvs FY2024 (Q4)
Operating Income
$4M
↓-53.5% -$4Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $226M | $214M |
| COGS | $49M | $39M |
| Gross Profit | $177M | $175M |
| R&D | $0 | $0 |
| SG&A | $78M | $73M |
| D&A | $9M | $4M |
| Other OpEx | $86M | $90M |
| Operating Income | $4M | $8M |
| Interest Exp. | $123K | $129K |
| Other Non-Op | $0 | $0 |
| Pretax Income | $4M | $8M |
| Tax | $4M | $4M |
| Net Income | $0 | $4M |
QuarterCharts · SEC EDGAR data · USNA · Comparing FY2026 (Q4) vs FY2024 (Q4)